This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Novel Use of Tramadol Hydrochloride in the Treatment of Tourette’s Syndrome

Nathan A. Shapira, Brian J. McConville, M. Lisa Pagnucco, Andrew B. Norman, and Paul E. Keck, Jr.

Published: April 15, 1997

Article Abstract

Letter to the Editor

Sir: Studies have demonstrated that symptoms of Tourette’s
syndrome can be attenuated by modulation of the opioid system.
However, the response to opioid agonists or antagonists
is often limited by side effects and the development of tolerance.
Additionally, these compounds have significant abuse potential.
The opioid tramadol hydrochloride (Ultram) has low abuse potential,
low physical dependency, and mild tolerance. It binds to
opioid receptors and also inhibits the reuptake of norepinephrine
and serotonin. We report the successful use of tramadol in the
treatment of a patient with severe Tourette’s syndrome.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 58

Quick Links: Movement Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...